Regenerative medicine has progressed a lot in past decade with stem cell therapy (SCT) being used for a number of devastating disease like Parkinson's,
1 Alzheimer's,
2 stroke,
3 spinal cord injury,
4 and heart disorders.
5 In ocular disorders, stem cells have been successfully used in ocular surface reconstruction
6 and also for inducing tolerance while doing allograft limbal transplants.
7 Some of the diseases, like optic and retinal neuropathies, acute onset of myocardial infarction, and stroke, would require immediate transplantation of stem cells for fast therapeutic recovery. The application of stem cells in hundreds of clinical trials would require these cells to be cryopreserved to meet the high dose demand at the time of treatment, which is one of the main goals for “off-the-shelf” SCT. However, there are no studies available about the multipotency and stemness of stem cells after long-term cryopreservation (>10 years). Harsh conditions of cryopreservation can alter the biological properties of stem cells, compromising their use for downstream clinical and research-based application.
8 There are vast studies available in the literature with contrasting findings.
9 An important study by Moll et al.
10 reported that continuously passaged early-passage fresh mesenchymal stem cells (MSCs) showed a better therapeutic outcome in patients with acute graft versus host disease (GvHD) as compared to cryopreserved MSCs when transplanted as intravenous injections. In another study, Francois et al.
11 showed that cell viability of freshly thawed MSCs was significantly very low as compared with cells that were maintained continuously in culture for more than 1 week. However, Luetzkendorf and colleagues
12 reported that the proliferation, viability, and immunosuppressive properties of MSCs remain intact after cryopreservation. Similarly, Katayama et al.
13 showed that peripheral blood stem cells maintain their viability even after 5 years of long-term cryopreservation. Gramlich et al.
14 reported that MSCs maintain their potency in retinal ischemia model after 7 to 30 days of cryopreservation. Working together with the Funderburgh group at the University of Pittsburgh, we first characterized the corneal stromal stem cells (CSSCs) as a rare population in human corneal stroma.
15 CSSCs have potency of multilineage differentiation.
15 CSSCs have been used in various applications related to ocular regeneration, like prevention and reduction of corneal scarring,
16–18 and also in generation of corneal tissues resembling in structure with human cornea.
19–23 In contrast, corneal fibroblasts, unlike CSSCs, do not have regenerative effects and rather induce fibrotic and inflammatory response in vivo.
18,24 The CSSCs can be easily obtained by biopsy from the corneal limbus,
16 and there can be a possibility of enhanced therapeutic benefit of CSSCs in corneal regeneration because these cells are natural progenitors of corneal keratocytes and are derived from neural crest. Thus, they are also an attractive candidate for autologous SCT in patients. However, there is no evidence available to date about the regenerative potential of CSSCs or any other ocular stem cells after long-term cryopreservation.